Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Transplant Cell Ther. 2021 Mar 22;27(6):507–516. doi: 10.1016/j.jtct.2021.03.015

Table 1.

Baseline Characteristics

BM Related PBSC Unrelated PBSC
Characteristic Fresh Cryo P Fresh Cryo P Fresh Cryo P
No. of patients 456 154 3030 1051 2028 678
Median age at transplant (y) 32.5 (0.6–79.8) 34.7 (0.4–75.1) .74 56.8 (3.7–76) 56.9 (7.6–77.7) .52 54.7 (0.9–83.4) 54.9 (0.9–77.9) .93
Male Sex (%) 235 (52) 80 (52) .73 1767 (58) 645 (61) .03 1220 (60) 394 (58) .21
Race (%) .29 .03 .007
 Caucasian 374 (82) 120 (78) 2440 (81) 871 (83) 1795 (89) 581 (86)
 African-American 21 (5) 10 (6) 161 (5) 60 (6) 72 (4) 32 (5)
 Other 22 (4) 10 (7) 228 (7) 60 (6) 70 (3) 31 (5)
 Missing 39 (9) 14 (9) 201 (7) 60 (6) 91 (4) 34 (5)
KPS >=90, n(%) 289 (63) 102 (66) .57 1688 (56) 612 (58) .16 1114 (55) 353 (52) .24
HCT-CI .39 .04 .97
 0 163 (36) 54 (35) 675 (22) 193 (18) 384 (19) 133 (20)
 1–2 139 (30) 42 (27) 872 (29) 305 (29) 574 (28) 193 (28)
 3+ 154 (34) 58 (38) 1483 (49) 553 (53) 1070 (53) 352 (52)
Primary disease .95 .66 .87
 AML 201 (44) 64 (42) 1230 (41) 454 (43) 906 (45) 291 (43)
 ALL 115 (25) 43 (28) 461 (15) 151 (14) 316 (16) 111 (16)
 CML 23 (5) 8 (5) 82 (3) 24 (2) 72 (4) 24 (4)
 MDS/MPD 82 (18) 29 (19) 855 (28) 274 (26) 447 (22) 160 (24)
 Other acute leukemia 14 (3) 5 (3) 31 (1) 14 (1) 32 (2) 10 (1)
 NHL 13 (3) 3 (2) 304 (10) 113 (11) 208 (10) 69 (10)
 Hodgkin lymphoma 8 (2) 2 (1) 67 (2) 21 (2) 47 (2) 13 (2)
DRI, n(%)
 Adult .92 .74 .58
  Low 25 (5) 8 (5) 196 (6) 72 (7) 163 (8) 56 (8)
  Intermediate 149 (33) 49 (32) 1734 (57) 582 (55) 997 (49) 335 (49)
  High 69 (15) 21 (14) 762 (25) 277 (26) 507 (25) 172 (25)
  Very high 13 (3) 5 (3) 104 (3) 36 (3) 123 (6) 42 (6)
 Pediatric (adult definition) .93 .76 .08
  Low 5 (1) 2 (1) 1 (0) 1 (0) 11 (1) 2 (0)
  Intermediate 70 (15) 24 (16) 13 (0) 2 (0) 23 (1) 5 (1)
  High 67 (15) 25 (16) 15 (0) 5 (0) 12 (1) 1 (0)
  Very high 0 0 1 (0) 0 2 (0) 1 (0)

HCT-CI indicate Hematopoietic Cell Transplantation Comorbidity index; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; MDS/MPD, myelodysplastic disease/myeloproliferative disease; NHL, non-Hodgkin’s lymphoma